Has Gregory Maniatis, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,932 in general payments to Gregory Maniatis, MD across 112 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gregory Maniatis, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gregory Maniatis, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gregory Maniatis, MD

Interventional Cardiology · Staten Island, NYNPI 1932499290

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Medtronic at 33.3% of the total. That places this record below the midpoint for interventional cardiology clinicians in NY, where the typical reported total is $8,047.

$7,932in general payments, 2019–2025

Across 112 payments — averaging $70.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$3K
Abbott$2K
Edwards Lifesciences$1K
Philips North America LLC$838
Boston Scientific$700
Spectrawave, Inc$320
plus $466 from 6 others

What the payments were for

Food & beverage$7,932100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	39	$2,643
Abbott	28	$1,748
Edwards Lifesciences	18	$1,217
Philips North America LLC	11	$838
Boston Scientific	5	$700
Spectrawave, Inc	2	$320
Teleflex LLC	1	$143
Terumo Medical Corporation	1	$131
Abiomed	3	$88
Shockwave Medical, Inc	2	$73
Heartflow, Inc.	1	$20
AbbVie	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

COREVALVE EVOLUT R$1,243
SAPIEN 3 Ultra RESILIA$470
MitraClip$421
CoreValve Evolut$361
HyperVue Imaging System$320
Starlight Imaging Catheter$320
DRAGONFLY OPSTAR$285
SYNERGY$276
(6575) Coronary Undivided$275
INSPIRIS RESILIA aortic valve$253
(BQ9) Coronary IVUS$230
MANTA$143
MetaCross$131
Glidesheath$131
AMPLATZER$128
CLARIA MRI QUAD CRT-D SURESCAN$127
Resolute$127
OPTIS$126
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$111
Dragonfly OCT$104

How this compares

$7,932 in reported general payments places this provider in the 45th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York →

Medicare billing

Part B allowed, 2024

$284,273

Medicare patients

569

Services billed

2,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	89	$90,723
EntrestoSacubitril/Valsartan	23	$30,647
Metoprolol Succinate	124	$1,739
Atorvastatin Calcium	119	$1,224
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide	17	$782
Amlodipine Besylate	55	$426
Losartan Potassium	34	$343
Torsemide	15	$263
Rosuvastatin Calcium	26	$260
Furosemide	48	$203
Pravastatin Sodium	16	$198
ClopidogrelClopidogrel Bisulfate	17	$191
Valsartan	12	$189
Amiodarone Hcl	12	$171
Hydrochlorothiazide	21	$127

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Staten Island

Sahil ParikhNew York$1.6M
Deepak BhattNew York$1.6M
Martin LeonNew York$1.5M
Evan ShlofmitzRoslyn$951K
Mohamed Azeem LatibBronx$816K
Yili HuangElmhurst$699K
Ali HaiderAstoria$492K
Sripal BangaloreNew York$482K
Ajay KirtaneNew York$462K
David CohenRoslyn$392K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →